Corcept Therapeutics Inc (CORT) Return on Investment ROI from the third quarter of 2026 to third quarter of 2025 and for the year 2026, average high and low, overall ranking from Sep 30 2026 to Sep 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Corcept Therapeutics Inc  (NASDAQ: CORT)


Corcept Therapeutics Inc's ROI from its third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Corcept Therapeutics Inc's ROI in the third quarter of 2026?
Corcept Therapeutics Inc achieved a return on average invested assets (ROI) of 22.08 % in its third quarter of 2026, this is above CORT's average return on investment of 3.36%.
Corcept Therapeutics Inc invested over the 12 months ending in its third quarter of 2026 $732 million

ROI has improved compared to 7.96% in the second quarter of 2026, due to net income growth.

Within the Healthcare sector 125 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the second quarter of 2026 from 1201 to 1222.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Investment Change TTM 7.96 % 0.16 % -1.13 % 6.01 % 15.94 %
Y / Y Net Income Change TTM 54.42 % -58.93 % -52.07 % 27.33 % 124.17 %
Investment (TTM) in Millions 856 735 666 671 651
Return On Investment (TTM) 22.08 % 7.96 % 7.06 % 14.64 % 15.44 %
CORT's Overall Ranking # 1222 # 1201 # 356 # 404 #
Seq. Investment Change TTM 7.53 % 2.94 % -1.41 % -1.08 % -0.25 %
Seq. Net Income Change TTM 198.15 % 16.13 % -52.45 % -6.21 % -20.71 %
Net Income (TTM) in Millions 162 54 47 98 105

CORT Company Profile >> Back to CORT Roi Comparisons >> See Annual CORT Return On Investment



Return On Investment CORT's Ranking
Within: No.
Industry # 47
Sector # 126
Overall # 1222

Return On Investment Statistics
High Average Low
131.42 %
3.36 %
-109.71 %
(Dec 31 2017)   (Dec 31 2014)



  News about Corcept Therapeutics Inc Return on Investment ROI

Corcept Therapeutics Appoints Roberto Vieira as President, Oncology amidst Recent Stock Dip

January 29, 2024


Combining Articles:
Corcept Therapeutics Incorporated, a leading commercial-stage company specializing in the discovery and development of medications to address severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating cortisol hormone effects, has appointed Roberto Vieira as the new President of Oncology. The announcement was made on January 29, 2024, by Joseph K. Belanoff, MD, Corcept s Chief Executive Officer.
Vieira, an experienced professional in the field, will report directly to Dr. Belanoff and join Corcept s Executive Team. This strategic move aims to bolster the company s efforts in the oncology sector. As an emerging area of focus within Corcept s diverse portfolio, having a dedicated leader in Oncology will enhance their capabilities and drive progress in developing innovative treatments.





Financial Statements
Corcept Therapeutics Inc's III. Quarter Investments $ 856 Millions CORT's Balance sheet
Corcept Therapeutics Inc's III. Quarter Income $ 127 Millions Quarterly CORT's Income Statement
CORT's Income by Division See CORT's Income by Division


CORT Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 671 700 517 511 376
Y / Y Investment Growth -4.17 % 35.35 % 1.19 % 35.81 % -28.24 %
Net Income in Millions 98 140 105 101 113
Y / Y Net Income Growth -29.74 % 32.45 % 4.15 % -9.98 % 6.13 %
Annual Return On Investment 14.64 % 19.97 % 20.4 % 19.82 % 29.91 %


Annual Roi Comment
In the fiscal year 2025 ROI decreased relative to the previous year to 14.64 %, due to deterioration of net income.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
CORT's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for CORT's Competitors
Subscribers only: Roi for Corcept Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for CORT's Customers

Other Ratios
CORT's Roa CORT's Inventory Turnover Ratio CORT's Growth Rates CORT's Dividend Statistics
CORT's Profitability Ratios CORT's Asset Turnover Ratio CORT's Dividend Growth
CORT's Roe CORT's Valuation Ratios CORT's Financial Strength Ratios CORT's Dividend Payout Ratio



Companies with similar Return On Investment at Sep 30 2026, within Healthcare Sector ROI
Idexx Laboratories Inc  52.51 %
Aurinia Pharmaceuticals Inc   45.04 %
Nurix Therapeutics Inc   44.12 %
Medpace Holdings Inc   41.14 %
Rallybio Corporation  36.04 %
Eli Lilly And Company  32.00 %
Caredx Inc   30.65 %
Zevra Therapeutics Inc   29.88 %
Acadia Pharmaceuticals Inc   26.89 %
Standard Biotools Inc   23.91 %
Iradimed Corporation  22.98 %
Corcept Therapeutics Inc  22.08 %
Resmed Inc   21.10 %
Alector Inc   20.83 %
Chemed Corporation  20.46 %
Halozyme Therapeutics Inc   19.64 %
Pro dex Inc   19.11 %
Dexcom Inc   18.92 %
Illumina Inc   18.74 %
Denali Therapeutics Inc   17.88 %
West Pharmaceutical Services Inc   17.65 %
Healthcare Services Group Inc   17.18 %
Neurocrine Biosciences Inc   16.94 %
Krystal Biotech Inc   16.91 %
Vertex Pharmaceuticals Inc  16.63 %
Intuitive Surgical Inc   16.30 %
Hca Healthcare Inc   15.54 %
Kiniksa Pharmaceuticals International Plc  15.45 %
Carlisle Companies Incorporated  13.64 %
Bristol myers Squibb Company  13.59 %

Date modified: 2026-11-05T14:33:37+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.